A Randomized Phase II Study of Pembrolizumab With or Without Defactinib, a Focal Adhesion Kinase Inhibitor Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
Phase of Trial: Phase II
Latest Information Update: 07 Jan 2020
Price : $35 *
At a glance
- Drugs Defactinib (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 03 Jul 2019 Planned End Date changed from 1 Feb 2023 to 1 May 2023.
- 03 Jul 2019 Planned primary completion date changed from 1 Feb 2023 to 1 May 2023.
- 11 Apr 2019 Status changed from not yet recruiting to recruiting.